Pharmaceuticals, Biotechnology & Life Sciences

Companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Includes companies specializing in protein-based therapeutics to treat human diseases. Excludes companies manufacturing products using biotechnology but without a health care application.

Companies engaged in the research, development or production of pharmaceuticals. Includes veterinary drugs.

Companies enabling the drug discovery, development and production continuum by providing analytical tools, instruments, consumables & supplies, clinical trial services and contract research services. Includes firms primarily servicing the pharmaceutical and biotechnology industries.

https://www.spcapitaliq.com/gicsmaps

Income Statment

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue 10,310,000,000 9,150,800,000 8,538,600,000 7,915,300,000 6,922,800,000 5,909,500,000 5,458,600,000 5,334,800,000 4,950,400,000 4,616,400,000
Cost of Goods Sold -4,466,700,000 -3,924,400,000 -3,761,200,000 -3,531,600,000 -3,326,800,000 -3,034,800,000 -2,605,900,000 -2,604,000,000 -2,391,400,000 -2,389,900,000
Gross Profit 5,843,300,000 5,226,400,000 4,777,400,000 4,383,700,000 3,596,000,000 2,874,700,000 2,852,700,000 2,730,800,000 2,559,000,000 2,226,500,000
Operating Costs -2,713,300,000 -2,509,900,000 -2,273,400,000 -2,003,400,000 -1,827,100,000 -1,247,200,000 -1,079,100,000 -1,073,500,000 -1,043,900,000 -916,000,000
Operating Profit 3,130,000,000 2,716,500,000 2,504,000,000 2,380,300,000 1,768,900,000 1,627,500,000 1,773,600,000 1,657,300,000 1,515,100,000 1,310,500,000
Financing Costs -166,900,000 -143,800,000 -162,900,000 -99,100,000 -79,100,000 -71,600,000 -59,600,000 -53,000,000 -47,700,000 -40,500,000
Pre-Tax Profit 2,963,100,000 2,572,700,000 2,341,100,000 2,281,200,000 1,689,800,000 1,555,900,000 1,714,000,000 1,604,300,000 1,467,400,000 1,270,000,000
Income Tax -588,100,000 -470,200,000 -422,400,000 -552,300,000 -352,400,000 -313,500,000 -335,000,000 -297,300,000 -251,100,000 -246,100,000
Net Profit 2,375,000,000 2,102,500,000 1,918,700,000 1,728,900,000 1,337,400,000 1,242,400,000 1,379,000,000 1,307,000,000 1,216,300,000 1,023,900,000

Balance Sheet

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Current Assets 7,389,700,000 6,446,200,000 5,540,100,000 4,993,700,000 4,602,100,000 3,818,000,000 3,339,100,000 3,207,600,000 3,259,300,000 3,445,100,000
Non-Current Assets 10,767,200,000 9,018,500,000 6,774,300,000 5,780,800,000 4,520,600,000 3,744,700,000 3,061,900,000 3,070,100,000 2,716,200,000 2,456,200,000
Assets 18,156,900,000 15,464,700,000 12,314,400,000 10,774,500,000 9,122,700,000 7,562,700,000 6,401,000,000 6,277,700,000 5,975,500,000 5,901,300,000
Current Liabilities 3,103,600,000 2,141,500,000 2,188,200,000 1,914,700,000 1,618,100,000 1,374,400,000 936,100,000 845,300,000 906,600,000 950,300,000
Non-Current Liabilities 6,672,000,000 6,795,600,000 4,874,900,000 4,779,900,000 4,340,800,000 3,621,100,000 2,718,000,000 2,270,400,000 2,062,100,000 1,474,300,000
Liabilities 9,775,600,000 8,937,100,000 7,063,100,000 6,694,600,000 5,958,900,000 4,995,500,000 3,654,100,000 3,115,700,000 2,968,700,000 2,424,600,000
Equity 8,381,300,000 6,527,600,000 5,251,300,000 4,079,900,000 3,163,800,000 2,567,200,000 2,746,900,000 3,162,000,000 3,006,800,000 3,476,700,000

Cash Flow Statement

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Cash Flow from Operating Activities 3,621,900,000 2,488,300,000 1,644,400,000 1,902,100,000 1,246,600,000 1,178,600,000 1,363,600,000 1,360,700,000 1,311,700,000 1,205,800,000
Cash Flow from Financing Activities -1,401,800,000 -642,700,000 -491,500,000 -371,500,000 -103,500,000 -362,400,000 -828,100,000 -1,137,100,000 -1,218,500,000 -194,700,000
Cash Flow from Investing Activities -1,673,200,000 -1,366,700,000 -1,287,300,000 -1,534,100,000 -862,900,000 -810,100,000 -413,300,000 -401,500,000 -449,500,000 -322,200,000
Net Change in Cash 546,900,000 478,900,000 -134,400,000 -3,500,000 280,200,000 6,100,000 122,200,000 -177,900,000 -356,300,000 688,900,000
Cash at the Beginning of the Period 1,151,300,000 657,800,000 812,700,000 843,000,000 555,300,000 555,500,000 606,300,000 759,800,000 1,168,100,000 514,600,000
Exchange Fluctuations 31,900,000 14,600,000 -20,500,000 -26,800,000 7,500,000 -6,300,000 -173,000,000 24,400,000 -52,000,000 -35,400,000
Cash at the End of the Period 1,730,100,000 1,151,300,000 657,800,000 812,700,000 843,000,000 555,300,000 555,500,000 606,300,000 759,800,000 1,168,100,000

Profitability

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Gross Margin 56.7% 57.1% 56.0% 55.4% 51.9% 48.6% 52.3% 51.2% 51.7% 48.2%
Operating Margin 30.4% 29.7% 29.3% 30.1% 25.6% 27.5% 32.5% 31.1% 30.6% 28.4%
Net Margin 23.0% 23.0% 22.5% 21.8% 19.3% 21.0% 25.3% 24.5% 24.6% 22.2%

Management Effectiveness

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Return on Assets 13.1% 13.6% 15.6% 16.0% 14.7% 16.4% 21.5% 20.8% 20.4% 17.4%
Return on Equity 28.3% 32.2% 36.5% 42.4% 42.3% 48.4% 50.2% 41.3% 40.5% 29.5%
Current Ratio 2.4 3.0 2.5 2.6 2.8 2.8 3.6 3.8 3.6 3.6
Debt to Equity Ratio 0.4 0.3 0.4 0.5 0.5 0.5 0.3 0.3 0.3 0.3

Valuation

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Share Price ($) 285.19 287.00 215.00 192.62 138.03 112.18 86.47 66.55 61.58 39.42
Ordinary Shares 455,128,517 454,048,707 453,138,632 452,400,784 453,251,764 456,608,747 464,832,827 474,788,269 487,462,182 506,929,847
Market Capitalisation ($) 129,798,101,763 130,311,978,909 97,424,805,880 87,141,439,014 62,562,340,985 51,222,369,238 40,194,094,551 31,597,159,302 30,017,921,168 19,983,174,569
Revenue per Share ($) 22.65 20.15 18.84 17.50 15.27 12.94 11.74 11.24 10.16 9.11
Earnings per Share ($) 5.22 4.63 4.23 3.82 2.95 2.72 2.97 2.75 2.50 2.02
Equity per Share ($) 18.42 14.38 11.59 9.02 6.98 5.62 5.91 6.66 6.17 6.86
Dividends per Share ($) 2.10 1.95 1.78 1.51 1.32 1.24 1.18 1.05 0.97 0.81
Dividend Yield 0.7% 0.7% 0.8% 0.8% 1.0% 1.1% 1.4% 1.6% 1.6% 2.1%
Price to Sales Ratio 12.6 14.2 11.4 11.0 9.0 8.7 7.4 5.9 6.1 4.3
Price to Earnings Ratio 54.7 62.0 50.8 50.4 46.8 41.2 29.1 24.2 24.7 19.5
Price to Book Ratio 15.5 20.0 18.6 21.4 19.8 20.0 14.6 10.0 10.0 5.7

Members